Bridge Biotherapeutics Current Valuation vs. Cash Flow From Operations
| 288330 Stock | KRW 4,050 445.00 9.90% |
For Bridge Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bridge Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bridge Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bridge Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bridge Biotherapeutics over time as well as its relative position and ranking within its peers.
Bridge |
Bridge Biotherapeutics Cash Flow From Operations vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bridge Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bridge Biotherapeutics value to that of its competitors to determine the firm's financial worth. Bridge Biotherapeutics is rated below average in current valuation category among its peers. It also is rated below average in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bridge Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bridge Biotherapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bridge Current Valuation vs. Competition
Bridge Biotherapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology & Medical Research industry is presently estimated at about 1.54 Trillion. Bridge Biotherapeutics claims roughly 29.26 Billion in current valuation contributing just under 2% to stocks in Biotechnology & Medical Research industry.
Bridge Cash Flow From Operations vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bridge Biotherapeutics |
| = | 29.26 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Bridge Biotherapeutics |
| = | (21.13 B) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Bridge Cash Flow From Operations Comparison
Bridge Biotherapeutics is rated below average in cash flow from operations category among its peers.
Bridge Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bridge Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bridge Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bridge Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Bridge Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Bridge Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bridge Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bridge Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bridge Biotherapeutics' important profitability drivers and their relationship over time.
Use Bridge Biotherapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Bridge Biotherapeutics Pair Trading
Bridge Biotherapeutics Pair Trading Analysis
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bridge Biotherapeutics position
In addition to having Bridge Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bridge Stock
To fully project Bridge Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bridge Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bridge Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.